Incyte is jumping aboard Agenus’ antibody discovery platform, signing up to partner on new immuno-oncology drugs with $60 million in cash and promises of up to $350 million in milestones. And the deal news quickly drove up Agenus’ shares by more than 30% in premarket trading.

…read more

Source: Incyte, Agenus partner on immuno-oncology targets in $410M deal


0 No comments